Melanie M Frigault Selected Research

1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazine

1/2021	A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
1/2020	Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
1/2020	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer.
1/2019	First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
9/2017	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
6/2015	The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Melanie M Frigault Research Topics

Disease

8	Neoplasms (Cancer) 01/2022 - 02/2005
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 06/2015
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021 - 01/2019
3	Disease Progression 01/2021 - 02/2020
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2021 - 10/2021
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2021 - 01/2021
2	Nausea 01/2021 - 09/2017
2	Headache (Headaches) 01/2021 - 01/2019
2	Cough 01/2021 - 01/2019
2	Diarrhea 01/2021 - 01/2019
2	Vomiting 01/2021 - 09/2017
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022
1	Neutropenia 01/2022
1	Hyponatremia 01/2022
1	Anemia 01/2022
1	Abdominal Pain (Pain, Abdominal) 01/2022
1	Dizziness (Lightheadedness) 01/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021
1	Contusions 01/2021
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 02/2020
1	Lymphocytosis 01/2020
1	Stomach Neoplasms (Stomach Cancer) 01/2020
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/2019
1	Carcinogenesis 01/2019
1	Edema (Dropsy) 09/2017
1	Fatigue 09/2017
1	Trisomy (Trisomies) 06/2015

Drug/Important Bio-Agent (IBA)

8	acalabrutinibIBA 11/2021 - 01/2019
6	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2021 - 06/2015
5	Agammaglobulinaemia Tyrosine KinaseIBA 11/2021 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2017
2	ibrutinibIBA 01/2021 - 01/2019
2	Sunitinib (Sutent)FDA Link 01/2020 - 06/2015
2	Proto-Oncogene Proteins c-metIBA 01/2019 - 06/2015
1	Cyclin-Dependent Kinase 9IBA 01/2022
1	Alkaline PhosphataseIBA 01/2022
1	vistusertibIBA 11/2021
1	durvalumabIBA 11/2021
1	tremelimumabIBA 11/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2021
1	Interleukin-6 (Interleukin 6)IBA 11/2021
1	CytokinesIBA 11/2021
1	Gefitinib (Iressa)FDA Link 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	Immunoglobulin Variable RegionIBA 01/2020
1	obinutuzumabIBA 01/2020
1	CrizotinibIBA 06/2015
1	ElementsIBA 08/2014
1	Pharmaceutical PreparationsIBA 08/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2005

Therapy/Procedure

4	Therapeutics 01/2022 - 08/2014
1	Immunotherapy 11/2021
1	Drug Therapy (Chemotherapy) 08/2014